Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673722 | 0.90 | GPR119 (0.58) | GPR119MAPTTP53HTTCTSB | |
| SCHEMBL390641 | 0.87 | GPR119 (0.86) | GPR119MAPTTP53HTTALDH1A1 | |
| SCHEMBL386411 | 0.85 | GPR119 (0.77) | GPR119MAPTTP53HTTCTSB | |
| SCHEMBL6041144 | 0.80 | GPR119 (0.92) | GPR119MAPTTP53HTTALDH1A1 | |
| SCHEMBL6041176 | 0.80 | ALDH1A1 (0.50) | GPR119MAPTTP53HTTCTSB | |
| SCHEMBL388361 | 0.80 | GPR119 (1.00) | GPR119MAPTTP53HTTALDH1A1 | |
| SCHEMBL390329 | 0.80 | GPR119 (0.82) | GPR119MAPTTP53HTTALDH1A1 | |
| SCHEMBL1673608 | 0.79 | GPR119 (0.81) | GPR119MAPTTP53HTTALDH1A1 | |
| SCHEMBL12733498 | 0.78 | GPR119 (0.86) | GPR119MAPTALDH1A1POLBKMT2A | |
| SCHEMBL5261829 | 0.78 | GPR119 (0.45) | GPR119MAPTTP53HTTCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | UGT1A1, GPR119, UGT1A3 | GPR119 2/4885MAPT 4467/4885TP53 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.